Compare abrdn Income Credit Strategies Fund (ACP) vs Ascendis Pharma A/S (ASND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs Ascendis Pharma A/S — how do they compare? abrdn Income Credit Strategies Fund trades at $5.14 (market cap $641.16M), while Ascendis Pharma A/S trades at $254.92 (market cap $16.67B). The key difference: Ascendis Pharma A/S is far larger — about 26× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays a 18.2% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ACP | ASND | |
|---|---|---|
Market Cap | $641.16M | $16.67B |
Sector | Financials | Health |
52-Week High | $5.98 | $277.18 |
52-Week Low | $5.01 | $189.74 |
Dividend Yield | 18.2% | — |
Enterprise Value | — | $17.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.14, up 1.18% today, with a bearish technical signal from moving averages. The stock shows a low P/E of 7.74 and P/B of 0.9, indicating potential undervaluation, while a high net income margin of 95.31% and consistent dividend payments highlight financial strength. Recent news confirms dividend declarations for 2026.
The outlook is mixed; attractive valuation and dividends offer opportunity, but volatile revenue, an unsustainable distribution rate flagged by analysts, and high leverage pose significant risks. Investor sentiment is cautious due to these fundamental concerns.
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →
